Annual SG&A:
$178.18M+$67.36M(+60.78%)Summary
- As of today, RXRX annual SG&A is $178.18 million, with the most recent change of +$67.36 million (+60.78%) on December 31, 2024.
- During the last 3 years, RXRX annual SG&A has risen by +$120.50 million (+208.91%).
- RXRX annual SG&A is now at all-time high.
Performance
RXRX SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly SG&A:
$41.63M-$5.03M(-10.77%)Summary
- As of today, RXRX quarterly SG&A is $41.63 million, with the most recent change of -$5.03 million (-10.77%) on September 30, 2025.
- Over the past year, RXRX quarterly SG&A has increased by +$3.87 million (+10.25%).
- RXRX quarterly SG&A is now -46.07% below its all-time high of $77.19 million, reached on December 31, 2024.
Performance
RXRX Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM SG&A:
-$6.84B-$715.50M(-11.69%)Summary
- As of today, RXRX TTM SG&A is -$6.84 billion, with the most recent change of -$715.50 million (-11.69%) on September 30, 2025.
- Over the past year, RXRX TTM SG&A has dropped by -$6.97 billion (-5302.08%).
- RXRX TTM SG&A is now -3101.50% below its all-time high of -$213.60 million.
Performance
RXRX TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Selling, General & Administrative Expenses Formula
SG&A = Total Operating Expenses - Cost of Goods Sold - Research & Development
RXRX Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +60.8% | +10.3% | -5302.1% |
| 3Y3 Years | +208.9% | +113.6% | -8546.4% |
| 5Y5 Years | +840.2% | +497.8% | -10000.0% |
RXRX Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +208.9% | -46.1% | +113.6% | -248.9% | at low |
| 5Y | 5-Year | at high | +840.2% | -46.1% | >+9999.0% | -3101.5% | at low |
| All-Time | All-Time | at high | +840.2% | -46.1% | >+9999.0% | -3101.5% | at low |
RXRX Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2025 | - | $41.63M(-10.8%) | $220.12M(+1.8%) |
| Jun 2025 | - | $46.65M(-14.6%) | $216.25M(+7.4%) |
| Mar 2025 | - | $54.65M(-29.2%) | $201.43M(+13.0%) |
| Dec 2024 | $178.18M(+60.8%) | $77.19M(+104.4%) | $178.18M(+35.5%) |
| Sep 2024 | - | $37.76M(+18.6%) | $131.46M(+7.0%) |
| Jun 2024 | - | $31.83M(+1.4%) | $122.90M(+3.0%) |
| Mar 2024 | - | $31.41M(+3.1%) | $119.36M(+7.7%) |
| Dec 2023 | $110.82M(+35.8%) | $30.46M(+4.3%) | $110.82M(+10.6%) |
| Sep 2023 | - | $29.20M(+3.2%) | $100.20M(+10.7%) |
| Jun 2023 | - | $28.29M(+23.7%) | $90.49M(+8.5%) |
| Mar 2023 | - | $22.87M(+15.3%) | $83.40M(+2.2%) |
| Dec 2022 | $81.60M | $19.84M(+1.8%) | $81.60M(+0.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2022 | - | $19.49M(-8.1%) | $80.96M(+4.9%) |
| Jun 2022 | - | $21.20M(+0.6%) | $77.17M(+10.5%) |
| Mar 2022 | - | $21.07M(+9.7%) | $69.82M(+21.0%) |
| Dec 2021 | $57.68M(+128.4%) | $19.20M(+22.4%) | $57.68M(+49.9%) |
| Sep 2021 | - | $15.69M(+13.3%) | $38.48M(+29.3%) |
| Jun 2021 | - | $13.85M(+55.0%) | $29.75M(+41.3%) |
| Mar 2021 | - | $8.94M(>+9900.0%) | $21.06M(+19.1%) |
| Dec 2020 | $25.26M(+33.3%) | - | - |
| Dec 2020 | - | $0.00(-100.0%) | $17.68M(0.0%) |
| Sep 2020 | - | $6.96M(+35.0%) | $17.68M(+65.0%) |
| Jun 2020 | - | $5.16M(-7.2%) | $10.72M(+92.8%) |
| Mar 2020 | - | $5.56M | $5.56M |
| Dec 2019 | $18.95M | - | - |
FAQ
- What is Recursion Pharmaceuticals, Inc. annual SG&A?
- What is the all-time high annual SG&A for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. annual SG&A year-on-year change?
- What is Recursion Pharmaceuticals, Inc. quarterly SG&A?
- What is the all-time high quarterly SG&A for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. quarterly SG&A year-on-year change?
- What is Recursion Pharmaceuticals, Inc. TTM SG&A?
- What is the all-time high TTM SG&A for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. TTM SG&A year-on-year change?
What is Recursion Pharmaceuticals, Inc. annual SG&A?
The current annual SG&A of RXRX is $178.18M
What is the all-time high annual SG&A for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high annual SG&A is $178.18M
What is Recursion Pharmaceuticals, Inc. annual SG&A year-on-year change?
Over the past year, RXRX annual SG&A has changed by +$67.36M (+60.78%)
What is Recursion Pharmaceuticals, Inc. quarterly SG&A?
The current quarterly SG&A of RXRX is $41.63M
What is the all-time high quarterly SG&A for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high quarterly SG&A is $77.19M
What is Recursion Pharmaceuticals, Inc. quarterly SG&A year-on-year change?
Over the past year, RXRX quarterly SG&A has changed by +$3.87M (+10.25%)
What is Recursion Pharmaceuticals, Inc. TTM SG&A?
The current TTM SG&A of RXRX is -$6.84B
What is the all-time high TTM SG&A for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high TTM SG&A is -$213.60M
What is Recursion Pharmaceuticals, Inc. TTM SG&A year-on-year change?
Over the past year, RXRX TTM SG&A has changed by -$6.97B (-5302.08%)